Panel Discussion: The Evolution of Development & Use Beyond Breast Cancer

Time: 10:00 am
day: Day One


• Sharing insights into future directions and what to anticipate as standards evolve for HER2 drugs in the clinic
• Addressing current treatment regimes and rational order of therapy
• Delving into combination thoughts and current status
• Understanding the current pitfalls in sequencing and selecting patients: how is HER2 high vs HER2 low
• Exploring potency, side effects, efficacy ratios and discussing how we can better connect pre-clinic to the clinic
• Overviewing the status of Gastric, CRC, Biliary, Bladder, NSCLC, CNS, paediatric and other relevant tumor indications
• Defining the conventional targeting and novel approaches in terms of efficacy and use